Workability in Patients With Seropositive Rheumatoid Arthritis

March 3, 2017 updated by: Carolin Berner, Kaiser Franz Josef Hospital
This study compares workability in subjects with seropositive rheumatoid arthritis (RA) in the working age with high and low disease activity. Further interest is to clarify the influence of frailty, functional ability and muscle strength on workability and to determine the effect of disease activity on selected physiological needs (sleep quality, sexual functioning). Methods include a physical examination, questionnaires and physical tests.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Chronic diseases like RA are negatively associated with workability and RA has been shown to be an economic burden for society and patients. RA patients seem also to be more prone to frailty which is characterized by slowed walking speed, low physical activity, and low grip strength. Also poor sleep has been shown to negatively influence work ability and the majority of patients with RA experience insomnia, general fatigue and mental fatigue. RA has also been shown affect sexual functioning.

This monocentric cross sectional study will be conducted at a Viennese rheumatological outpatient clinic and day hospital on about 100 seropositive RA patients. The primary objective of this study is to compare workability in subjects with seropositive RA in the working age with high and low disease activity. Secondary interest is to clarify the influence of frailty, functional ability and muscle strength on workability and to determine the effect of disease activity on selected physiological needs (sleep quality, sexual functioning). Disease activity will be assessed during the patient's routine visit at the clinic via the clinical disease activity index (CDAI). Workability will be determined by the Work Ability Index questionnaire. The influencing determinants frailty and functional disability will be also assessed via questionnaires and/or with physical examinations (Survey of Health, Ageing and Retirement in Europe Frailty instrument, Short Physical Performance Battery, Health Assessment Questionnaire-Disability Index). For muscle strength assessment hand grip and maximum quadriceps strength will be measured . Contributing physiologic needs quality sleep and sexual functioning will be additionally determined vial self reported questionnaire (Medical Outcome Study -Sleep Scale, Index for sexual functioning).

In order to compare patients with low and high disease activity regarding metric data (like sleep quality or sexual functioning) unpaired Students t-tests (given normal distributed data and homogeneous variances), Welch corrected unpaired Student t-tests (in case of normal distributed data but heterogenous variances) or Mann-Whitney-U tests (in case of skewed data) will be used. Kolmogorov-Smirnov and Levene tests will be used to test for normal distribution and homogenous variances.To assess the impact of frailty, functional ability, muscle strength on workability (high versus low) binary logistic regression will be applied. In general the alpha level is set to 5%.

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Seropositive rheumatoid arthritis according to EULAR Criteria
  • Age ≥18 and ≤65 years

Exclusion Criteria:

  • Cannot understand questionnaires in the languages provided (German , English, Turkish, Serb o-Croatian)
  • Cannot understand instructions for physical tests/assessments.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Single arm assessment
Cross sectional assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning of rheumatoid arthritis patients with different disease activity levels.
Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Workability
Time Frame: Day 1
Self-reported work ability will be measured by the work ability index (WAI). The WAI is a questionnaire consisting of seven subscales: current work ability compared with the lifetime best; work ability in relation to the demands of the job; number of current diseases diagnosed by a physician; estimated work impairment due to disease; sick leave during the past 12 month; own prognosis of work ability 2 years from now; and mental resources. The cumulative index of WAI ranges from 7 to 49 points. It is then divided into 4 categories: poor (7-27 points), moderate (28-36 points), good (37-43 points) and excellent work ability (44-49 points).
Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional Disability
Time Frame: Day 1
Extend of the patients´ self-reported functional disability will be assessed by the Health Assessment Questionnaire Disability Index (HAQ -DI). There are 20 questions in eight categories of functioning - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Self-reported difficulties to perform these activities are scored on a scale from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). For any component question, highest score determines the score for that respective domain. The overall disability index is a value between 0 ( no functional disability) and 3 (severe functional disability) representing the average score across the domains.
Day 1
Frailty
Time Frame: Day 1
Frailty will be assessed with the SHARE Frailty Instrument (SHARE- FI).The assessment comprises 5 variables: grip strength measurement and 4 questions related to weakness, exhaustion, slowness and the activity level. Using the 5 variables DFactor scores (DFS) will be calculated using the gender specific SHARE-FI formula. For each subject the frailty score will be computed and subjects will then be categorized as non-frail, pre-frail, or frail.
Day 1
Lower-extremity function
Time Frame: Day 1
Lower-extremity function will be measured with the short physical performance battery (SPPB). The SPPB is a group of measures including gait speed, chair stand and balance tests. Each test a five-level categorical score will be assessed, with 0 representing inability to complete the test and 4 representing the highest level of performance. The summary score ranges from 0 (worst performance) to 12 (best performance).
Day 1
Musculus quadriceps femoris strength
Time Frame: Day1
Quadriceps muscle strength will be measured with an isokinetic dynamometer.Strength will be assessed 3 times for both legs with a 2 minute break between the measurements. Per software analysis maximum peak value of every leg will be determined on the basis of power vs. time curve. Mean value of both legs will be used in the statistical analysis.
Day1
Hand grip strength
Time Frame: Day1
Maximum grip strength will be measured with a portable hydraulic hand dynamometer. Three maximum voluntary grip strength contractions will be taken for each hand. Measurements will be done in alternating order with a 2 minutes break between each measurement. The mean value of each hand will be taken for analysis.
Day1
Quality of sleep
Time Frame: Day1
The patients´ quality of sleep will be assessed with the MOS Sleep Scale (MOS -SS) questionnaire.The MOS-SS is a 12-item self -report questionnaire referring to a retrospective assessment over the past 4 weeks. The MOS measures 6 sleep dimensions: Initiation (time to fall asleep in minutes), quantity (hours of sleep each night), maintenance, respiratory problems, perceived adequacy and somnolence. The last 4 items will be assessed via a 6-item scale ranging from "all the time" to "none of the time". The questionnaire yields 2 sleep problem indexes and 6 scores.
Day1
Sexual functioning
Time Frame: Day1
Sexual functioning will be measured via self-assessment questionnaire individually designed for this study.The questionnaire consists of two sections addressing sexual disability (difficulties in performing sexual intercourse) represented by question 1 and sexual drive ( reflected in sexual desire and satisfaction) represented by question 2-5. Scoring ranges from 1-10 and anchor points are set according to the question. Overall sexual functioning score ranges from 5 points (poor sexual functioning) to max 50 points.
Day1

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
IL-6
Time Frame: Day1
IL-6 levels will be measured in the blood. Standard venous blood sampling.
Day1
TNF-alpha
Time Frame: Day1
TNF-alpha levels will be measured in the blood. Standard venous blood sampling.
Day1
CRP
Time Frame: Day 1
CRP-alpha levels will be measured in the blood. Standard venous blood sampling.
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Chair: Thomas Dorner, Assoc Prof, MD, MPH, Institute of Social Medicine and Centre of Public Health
  • Principal Investigator: Ludwig Erlacher, Prof. MD, Kaiser Franz Josefs Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2015

Primary Completion (Actual)

August 1, 2016

Study Completion (Actual)

November 1, 2016

Study Registration Dates

First Submitted

July 10, 2015

First Submitted That Met QC Criteria

October 19, 2015

First Posted (Estimate)

October 21, 2015

Study Record Updates

Last Update Posted (Actual)

March 6, 2017

Last Update Submitted That Met QC Criteria

March 3, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Seropositive Rheumatoid Arthritis

Clinical Trials on Cross sectional assessment

Subscribe